New arthritis drug shows promise in major trial
NCT ID NCT06738719
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an injectable drug called CT-P13 in 192 adults with moderate-to-severe rheumatoid arthritis. The goal was to see if it reduces joint pain and swelling better than a placebo. Participants received either the drug or a dummy shot, and researchers measured improvement after 12 weeks using standard arthritis scores.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinika Reuma Park Sp. z.o.o
Warsaw, 02-665, Poland